Report: Biotech licensing, M&A deals dropped in 2012

04/1/2013 | Genetic Engineering & Biotechnology News

Biotech and biopharmaceutical firms struck fewer licensing and acquisition deals in 2012 compared with 2011, perhaps fueled by greater confidence in drug pipelines and fewer worries about patent expirations, according to a new report from EP Vantage. Total licensing-deal value declined 19%, to $20.9 billion, and the number of products licensed dropped from 1,037, to 759. Merger and acquisition deals reached $42.6 billion, down 24%.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX